TWI454468B - 作為組織胺ｈ３受體拮抗劑之氮雜環丁烷及環丁烷 - Google Patents

作為組織胺ｈ３受體拮抗劑之氮雜環丁烷及環丁烷 Download PDF

Info

Publication number
TWI454468B
TWI454468B TW098115068A TW98115068A TWI454468B TW I454468 B TWI454468 B TW I454468B TW 098115068 A TW098115068 A TW 098115068A TW 98115068 A TW98115068 A TW 98115068A TW I454468 B TWI454468 B TW I454468B
Authority
TW
Taiwan
Prior art keywords
carbonyl
cyclobutyl
azetidin
oxy
diazepane
Prior art date
Application number
TW098115068A
Other languages
English (en)
Chinese (zh)
Other versions
TW201006820A (en
Inventor
Adam James Davenport
David James Hallett
Massimo Corsi
Original Assignee
Evotec Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evotec Ag filed Critical Evotec Ag
Publication of TW201006820A publication Critical patent/TW201006820A/zh
Application granted granted Critical
Publication of TWI454468B publication Critical patent/TWI454468B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
TW098115068A 2008-05-08 2009-05-07 作為組織胺ｈ３受體拮抗劑之氮雜環丁烷及環丁烷 TWI454468B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08155915 2008-05-08
US13946108P 2008-12-19 2008-12-19

Publications (2)

Publication Number Publication Date
TW201006820A TW201006820A (en) 2010-02-16
TWI454468B true TWI454468B (zh) 2014-10-01

Family

ID=39720542

Family Applications (1)

Application Number Title Priority Date Filing Date
TW098115068A TWI454468B (zh) 2008-05-08 2009-05-07 作為組織胺ｈ３受體拮抗劑之氮雜環丁烷及環丁烷

Country Status (9)

Country Link
US (1) US8691804B2 (cg-RX-API-DMAC10.html)
EP (1) EP2300422B1 (cg-RX-API-DMAC10.html)
JP (1) JP5780954B2 (cg-RX-API-DMAC10.html)
CN (1) CN102015636B (cg-RX-API-DMAC10.html)
BR (1) BRPI0913057A2 (cg-RX-API-DMAC10.html)
CA (1) CA2721303C (cg-RX-API-DMAC10.html)
IL (1) IL208613A (cg-RX-API-DMAC10.html)
TW (1) TWI454468B (cg-RX-API-DMAC10.html)
WO (1) WO2009135842A1 (cg-RX-API-DMAC10.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0815591B8 (pt) 2007-08-22 2021-05-25 Astrazeneca Ab composto, composição farmacêutica, e, uso de um composto.
EP2391617B1 (en) 2009-02-02 2015-11-11 Evotec AG Azetidines as histamine h3 receptor antagonists
TW201039825A (en) 2009-02-20 2010-11-16 Astrazeneca Ab Cyclopropyl amide derivatives 983
CN102471235A (zh) * 2009-07-11 2012-05-23 拜耳医药股份有限公司 利用环烷基的放射性标记方法
AU2011218491C1 (en) 2010-02-18 2015-05-14 Astrazeneca Ab Processes for making cyclopropyl amide derivatives and intermediates associated therewith
EA201291384A1 (ru) * 2010-07-06 2013-07-30 Астразенека Аб Терапевтические агенты 976
EA023260B1 (ru) 2011-02-23 2016-05-31 Сувен Лайф Сайенсиз Лимитед Новые соединения в качестве лигандов гистаминовых h-рецепторов
UY34194A (es) 2011-07-15 2013-02-28 Astrazeneca Ab ?(3-(4-(espiroheterocíclico)metil)fenoxi)azetidin-1-il)(5-(fenil)-1,3,4-oxadiazol-2-il)metanona en el tratamiento de la obesidad?
WO2013151982A1 (en) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Methods and compounds useful in treating pruritus, and methods for identifying such compounds
CA2878217C (en) 2012-08-23 2016-05-17 Suven Life Sciences Limited Acrylamide compounds as histamine h3 receptor ligands
EP2905276A4 (en) * 2012-09-05 2016-03-09 Zhejiang Hisun Pharm Co Ltd CRYSTALLINE FORMS OF AZETIDINONE COMPOUNDS AND MANUFACTURING METHOD
US20230130739A1 (en) 2020-03-26 2023-04-27 Cyclerion Therapeutics, Inc. DEUTERATED sGC STIMULATORS
CN112279809A (zh) * 2020-09-23 2021-01-29 山东省海洋化工科学研究院 一种2-氰基-4-氟吡啶的制备方法
CN115073276A (zh) * 2022-07-15 2022-09-20 济南大学 一种泊沙康唑主环杂质的制备及控制方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003004480A2 (en) * 2001-07-02 2003-01-16 Novo Nordisk A/S Substituted piperazine and diazepanes as histamine h3 receptor agonists

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4956359A (en) 1985-02-28 1990-09-11 A. H. Robins Company, Inc. 3-aryloxy and 3-arylthioazetidinecarboxamides as anticonvulsants and antiepileptics
ZA861210B (en) 1985-02-28 1987-10-28 Robins Co Inc A H 3-aryloxyazetidinecarboxamides as anticonvulsants and antiepileptics
US6559140B2 (en) * 2000-03-09 2003-05-06 Abbott Laboratories Cyclic and bicyclic diamino histamine-3 receptor antagonists
DE10150310A1 (de) 2001-10-11 2003-04-24 Bayer Ag Substituierte Piperazincyclohexancarbonsäureamide und ihre Verwendung
US20080045506A1 (en) 2004-10-15 2008-02-21 Glaxo Group Limited Pyrrolidine Derivatives as Histamine Receptors Ligands
ATE488496T1 (de) 2005-06-22 2010-12-15 Pfizer Prod Inc Histamin-3-rezeptorantagonisten
US8158673B2 (en) * 2005-10-27 2012-04-17 Pfizer Inc. Histamine-3 receptor antagonists
CA2634235A1 (en) * 2005-12-21 2007-07-05 Schering Corporation Combination of an h3 antagonist/inverse agonist and an appetite suppressant
BRPI0707916A2 (pt) 2006-01-13 2011-05-17 Hoffmann La Roche compostos, processo para a sua manufatura, composições farmacêuticas que os compreendem e uso destes compostos
US8106208B2 (en) * 2006-05-18 2012-01-31 Albireo Ab Benzamide compounds that act as NK receptor antagonists
CN105712977B (zh) * 2007-11-20 2021-06-29 詹森药业有限公司 作为组胺h3受体调节剂的环烷基氧基吡啶化合物和杂环烷基氧基吡啶化合物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003004480A2 (en) * 2001-07-02 2003-01-16 Novo Nordisk A/S Substituted piperazine and diazepanes as histamine h3 receptor agonists

Also Published As

Publication number Publication date
CN102015636B (zh) 2014-08-13
IL208613A (en) 2015-07-30
EP2300422A1 (en) 2011-03-30
IL208613A0 (en) 2010-12-30
US8691804B2 (en) 2014-04-08
JP2011519891A (ja) 2011-07-14
BRPI0913057A2 (pt) 2015-10-13
TW201006820A (en) 2010-02-16
WO2009135842A1 (en) 2009-11-12
JP5780954B2 (ja) 2015-09-16
CA2721303A1 (en) 2009-11-12
US20110105459A1 (en) 2011-05-05
EP2300422B1 (en) 2014-11-05
CA2721303C (en) 2016-06-28
CN102015636A (zh) 2011-04-13
HK1155749A1 (en) 2012-05-25

Similar Documents

Publication Publication Date Title
EP2300422B1 (en) Azetidines as histamine h3 receptor antagonists
AU2023202086B2 (en) Antagonists of the muscarinic acetylcholine receptor M4
RU2691629C1 (ru) Производные имидазопиримидина в качестве модуляторов активности tnf
EP2766360B1 (en) Soluble guanylate cyclase activators
IL275058B2 (en) Sulfonylurea derivatives as modulators of the NLRP3 inflammasome
CN105228995B (zh) 取代的哌啶化合物以及它们作为食欲素受体调节剂的用途
JP2021510707A (ja) Ｉｌ−１７モジュレータとしての縮合イミダゾール誘導体
KR20200044038A (ko) 3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체 및 이의 용도
JP2021506848A (ja) Ｅ３ユビキチンリガーゼ部分を持つｅｇｆｒを有する二官能性阻害剤
TW201623304A (zh) Ｒｏｒｃ２的經甲基及三氟甲基取代之吡咯並吡啶調節劑及其使用方法
CA2555800C (en) Piperidinylcarbonyl-pyrrolidines and their use as melanocortin agonists
JP2024508547A (ja) ベンゾ［ｃ］［２，６］ナフチリジン誘導体、組成物およびその治療的使用
JP2021528398A (ja) ＲＯＲγＴのモジュレーターとしての６−アミノピリジン−３−イルピラゾール
TW202519211A (zh) 經取代之胺基吡啶化合物及用其治療疾病之方法
TW201030000A (en) (Dihydro) naphthyridinone derivatives as histamine H3 receptor antagonists
JP6370294B2 (ja) 環状アミノメチルピリミジン誘導体
CN115427409B (zh) 作为trpv4拮抗剂的嘧啶-4(3h)-酮衍生物
JP2023545065A (ja) オートタキシン抑制剤化合物
CA2804924C (en) Substituted pyridine compound
TWI449700B (zh) 作為組織胺ｈ３受體拮抗劑之三亞甲亞胺類
WO2017018475A1 (ja) 新規リンカー部位を持つ縮合ピラゾール誘導体およびその医薬用途
US20240059677A1 (en) Substituted pyrimidine derivatives as nicotinic acetylcholinesterase receptor alpha 6 modulator
HK1155749B (en) Azetidines and cyclobutanes as histamine h3 receptor antagonists
HK1234388A1 (en) Methyl-and trifluoromethyl-substituted pyrrolopyridine modulators of rorc2 an methods of use thereof
JP2016108326A (ja) 環状アミノメチルピリミジン誘導体からなる医薬

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees